Explanipedia

Recasting of Periodontal Diagnosis Open

Deepa S. Subramaniam, Bhumimathan Swamikannu, R. Narasimha Raghavan, V Keshavan, Karthikeyan P. Rajendran , et al. · 2025

A BSTRACT The very beginning of periodontal diagnosis began with ancient civilizations. The development of periodontology as a specialized discipline in the 20 th century resulted in the creation of uniform diagnostic standards and classif…

Comparison of Serum Magnesium Levels in Well-Controlled and Poorly Controlled Bronchial Asthma Among Children and Healthy Controls at a Tertiary Care Hospital Open

Kavitha Raja, Dr.Abarna S, Nithiyapriya, Deepa S. Subramaniam · 2025

Background: Asthma is one of the most common chronic diseases worldwide and has been increasing in prevalence over the last few decades. Magnesium ion has an inhibitory action on smooth muscle contraction, histamine release from mast cells…

Biphasic Calcium Phosphate in the Extraction Socket Preservation: A Systematic Review Open

S Mohanasatheesh, Anitha Balaji, Deepa S. Subramaniam, Vishnu Ganapathy, Karthikeyan P. Rajendran , et al. · 2024

A BSTRACT Introduction: Various studies have suggested use of socket grafting materials after dental extraction for socket preservation. However, there is no single material that has been accepted as standard for preserving the socket. The…

MEDI5752FINALSupplementaryMaterial.docx from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells Open

Simon J. Dovedi, Matthew J. Elder, Chunning Yang, Suzanne I. Sitnikova, Lorraine Irving , et al. · 2023

Supplementary Materials and Methods, and Supplementary Figures

Data from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells Open

Simon J. Dovedi, Matthew J. Elder, Chunning Yang, Suzanne I. Sitnikova, Lorraine Irving , et al. · 2023

The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a…

MEDI5752FINALSupplementaryMaterial.docx from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells Open

Simon J. Dovedi, Matthew J. Elder, Chunning Yang, Suzanne I. Sitnikova, Lorraine Irving , et al. · 2023

Supplementary Materials and Methods, and Supplementary Figures

Data from Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells Open

Simon J. Dovedi, Matthew J. Elder, Chunning Yang, Suzanne I. Sitnikova, Lorraine Irving , et al. · 2023

The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is commensurate with significant immune-related adverse events suboptimally limiting the doses of anti-CTLA4 mAb that can be used. MEDI5752 is a…

Surgical Excision of Hypertrophic Tissue and Retrieval of Orthodontic Mini-implant using Diode Laser- A Rare Case Report Open

Evangeline Ida, V Ramya, Anitha Balaji, Deepa S. Subramaniam, Dhivya Darshani. · 2023

Orthodontic mini-implants or transient anchorage devices can be used to shift difficult teeth. There is substantial evidence showing the effectiveness of Temporary Anchorage Devices (TAD) and their anchorage requirements. However, there ar…

LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial Open

M-J. Ahn, S-W. Kim, Enric Carcereny, Laura Rodríguez, Jorge Oliveira , et al. · 2022

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors Open

Rachel E. Sanborn, Michael J. Pishvaian, Margaret K. Callahan, Amy Weise, Branimir I. Šikić , et al. · 2022

Background Phase 1/2 dose-escalation and expansion study evaluating varlilumab, a fully human agonist anti-CD27 mAb, with nivolumab in anti-PD-1/L1 naïve, refractory solid tumors. Methods Phase 1 evaluated the safety of varlilumab (0.1–10 …

A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer Open

Chul Kim, Stephen V. Liu, Jennifer Crawford, Tisdrey Torres, Vincent Chen , et al. · 2021

Background Osimertinib is an effective first-line therapy option for EGFR -mutant NSCLC, but virtually all patients develop resistance. CRIPTO, through Src activation, has been implicated in resistance to EGFR tyrosine kinase inhibitor (EG…

A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies Open

Neel Trivedi, Samantha Armstrong, Hongkun Wang, Marion L. Hartley, John F. Deeken , et al. · 2021

Background Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combi…

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial Open

David A. Reardon, Tae Min Kim, Jean‐Sébastien Frénel, Matteo Simonelli, Juanita Lopez , et al. · 2021

Background Current treatments for recurrent glioblastoma offer limited benefit. The authors report the antitumor activity and safety of the anti–programmed death 1 (anti–PD‐1) immunotherapy, pembrolizumab, in programmed death ligand 1 (PD‐…

Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US Open

Amanda M. Kong, Melissa Pavilack, Hairong Huo, Rahul Shenolikar, Meghan Moynihan , et al. · 2021

NSCLC-related HRUC, especially those attributable to radiation treatment, were higher among patients with BM. Future research should compare the potential for CNS-active EGFR-TKIs vs first-/second-generation EGFR-TKIs combined with radioth…

Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung Open

Chul Kim, Stephen V. Liu, Deepa S. Subramaniam, Tisdrey Torres, Massimo Loda , et al. · 2020

Background Lutathera is a 177 Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti…

Implementation of the Smoking Treatment and Recovery (STAR) program: healthy cancer survivorship through integrated tobacco control Open

Kathryn L. Taylor, Shelby Fallon, Deepa S. Subramaniam, Kimberly M. Davis, Chan To , et al. · 2019

GENE-41. UNDERSTANDING THE DIFFERENCES IN ADOLESCENT AND YOUNG ADULT (AYA) GLIOMAS AND OLDER ADULT (OA) GLIOMAS BASED ON FUNCTIONAL MOLECULAR SUBGROUPS Open

Catherine Bi, Ashwin Subramaniam, Joanne Xiu, Amy B. Heimberger, Sharon K. Michelhaugh , et al. · 2019

BACKGROUND Gliomas in the AYA population (15–39 years of age) have unique biological characteristics and need to be better characterized. METHODS Glioma tumors in AYA subjects and subjects >65 years of age (OA) were analyzed by next genera…

P2.01-100 Spectrum of EGFR Exon 20 Insertion Mutations and Co-Occurring Genetic Alterations in Patients with Non-Small-Cell Lung Cancer Open

Gabriela Bravo, Misako Nagasaka, Peizhi Ma, Abdul Rafeh Naqash, Hirva Mamdani , et al. · 2019

P1.12-04 A Phase I Study of the 177Lu-DOTA0-Tyr3-Octreotate in Combination with Nivolumab in Patients with Extensive-Stage Small Cell Lung Cancer Open

C. Kim, Deepa S. Subramaniam, Stephen V. Liu, T. Torres, Giuseppe Esposito , et al. · 2019

MA09.01 A Phase I/II Trial of Dasatinib and Osimertinib in TKI Naïve Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Open

C. Kim, Stephen V. Liu, J. Crawford, Deepa S. Subramaniam, Giuseppe Giaccone · 2019

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies Open

Filipa Lynce, Hongkun Wang, Emanuel F. Petricoin, Paula R. Pohlmann, Brandon G. Smaglo , et al. · 2019

Electromagnetic fields alter the motility of metastatic breast cancer cells Open

Ayush Arpit Garg, Travis H. Jones, Sarah M. A. Moss, Sanjay Mishra, Kirti Kaul , et al. · 2019

Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis Open

Ben Creelan, M. Usman Ahmad, Frank J. Kaszuba, Farah Khalil, Allison W. Welsh , et al. · 2019

Background Juvenile-onset recurrent respiratory papillomatosis (JO-RRP) is a human papilloma virus-mediated progressive benign neoplasm that affects children and young adults. Primary management consists of regular surgical debulking to ma…

Editorial: Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment Open

Lizza Hendriks, Deepa S. Subramaniam, Anne‐Marie C. Dingemans · 2018

EDITORIAL article Front. Oncol., 06 November 2018Sec. Thoracic Oncology Volume 8 - 2018 | https://doi.org/10.3389/fonc.2018.00511

RARE-05. TUMOR PROFILING REVEALS EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) AND ENHANCED IMMUNE SUPPRESSION IN GLIOSARCOMAS RELATIVE TO GLIOBLASTOMA Open

Christopher Dardis, Surasak Phuphanich, Nader Sanai, Joanne Xiu, Sandeep Mittal , et al. · 2018

BACKGROUND: Gliosarcoma (GS) accounts for approximately 2% of WHO grade 4 gliomas and have a worse prognosis relative to glioblastoma (GBM). Epithelial-to-mesenchymal transition (EMT) is well recognized in a variety of tumors of ectodermal…

RARE-22. FREQUENT HIGH TUMOR MUTATIONAL BURDEN (TMB) AND PD-L1 EXPRESSION IN PRIMARY CNS LYMPHOMA (PCNSL) Open

Ashley Sumrall, Surasak Phuphanich, David Spetzler, Zoran Gatalica, Joanne Xiu , et al. · 2018

BACKGROUND: PD-1 and PD-L1 expression has not been well-described in PCNSL. In one report of 20 PCNSL tumors, PD-1 and PD-L1 expression on tumor cells (TC), tumor-infiltrating lymphocytes (TIL), or tumor-associated macrophages (TAM) was se…

Dramatic Response to Sequential BRAF Inhibition in BRAF V600E–Mutant Metastatic Lung Adenocarcinoma Open

Sushma Jonna, Giuseppe Giaccone, Ross W. Filice, Jenna W. Kramer, Deepa S. Subramaniam · 2018

ATIM-23. ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA (rGBM): PHASE 2 CLINICAL TRIAL RESULTS Open

David A. Reardon, Thomas Kaley, Fábio M. Iwamoto, Joachim M. Baehring, Deepa S. Subramaniam , et al. · 2018

CD27 is a key immunostimulatory molecule that enhances T cell survival, activation and effector function, as well as proliferation and cytotoxic activity of NK cells. Preclinical studies demonstrate synergistic activity of PD-(L)1 blockade…

Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk Open

Michael Repka, Siyuan Lei, L. D. Campbell, Simeng Suy, Jean-Marc Voyadzis , et al. · 2018

Purpose/Objective: High-grade glioma is the most common primary malignant tumor of the CNS, with death often resulting from uncontrollable intracranial disease. Radiation dose may be limited by the tolerance of critical structures, …

P01.058 Higher immune associated markers (PD-L1, PD-1, TMB, MSI) in gliosarcoma compared to glioblastoma. Open

Surasak Phuphanich, Nader Sanai, Joanne Xiu, Sandeep Mittal, Sharon K. Michelhaugh , et al. · 2018

Gliosarcomas (GS) are rare histological glioblastoma (GB) variants with glial and mesenchymal components. GS has been reported to have a similar genetic profile to primary GB. In a small series of GS, tissue from both the glial and sarcoma…

Deepa S. Subramaniam YOU? Author Swipe